Skip header and navigation

3 records – page 1 of 1.

The impact of drug vintage on patient survival: a patient-level analysis using Quebec's provincial health plan data.

https://arctichealth.org/en/permalink/ahliterature150607
Source
Value Health. 2009 Sep;12(6):847-56
Publication Type
Article
Date
Sep-2009
Author
Frank R Lichtenberg
Paul Grootendorst
Marc Van Audenrode
Dominick Latremouille-Viau
Patrick Lefebvre
Author Affiliation
Graduate School of Business, Columbia University, New York, NY, USA.
Source
Value Health. 2009 Sep;12(6):847-56
Date
Sep-2009
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Chronic Disease - drug therapy - mortality
Comorbidity
Databases, Factual
Drug Industry - statistics & numerical data - trends
Female
Humans
Longevity
Male
National Health Programs
Organizational Innovation
Prescription Drugs - economics - therapeutic use
Proportional Hazards Models
Quebec
Risk factors
Sex Factors
Survival Analysis
Survival Rate
Abstract
There is some debate about the value received for the money spent on prescription drugs. Some argue that most drug spending is on "me-too" drugs--drugs that provide only marginal health gains. Others suggest that the opposite is true--new drugs offer good value for money and are well worth the cost. To provide evidence on this issue, we evaluated the impact of drug innovation on the longevity of Canadians.
We analyzed patient-level claims data from Quebec's provincial health plan. We selected elderly patients with continuous health coverage dispensed at least one drug prescription in each year of the study period, 1997 to 2006. Drug vintage was defined as the active ingredient's earliest marketed date. We estimated the impact of drug vintage on patient survival using a time-varying Cox proportional hazards model that controlled for year indicator variables, patient age, sex, region of residence, low income status, medical services use, concomitant drug use, and comorbidities.
Of the 102,743 subjects in the study population, 14,154 (14%) died during the study period. Mean patient age was 68 years; 59% were women. Our survival models indicated that the use of newer medications was associated with a statistically significant mortality risk reduction (hazard ratio: 0.522; 95% confidence interval: 0.476 to 0.572, P
PubMed ID
19490554 View in PubMed
Less detail

Increased introduction, advertising, and sales of preventive drugs during 1986-2002 in Sweden.

https://arctichealth.org/en/permalink/ahliterature168720
Source
J Ambul Care Manage. 2006 Jul-Sep;29(3):238-49
Publication Type
Article
Author
J Lars G Nilsson
Arne Melander
Author Affiliation
NEPI Foundation, Stockholm, Sweden. lars.nilsson@nepi.net
Source
J Ambul Care Manage. 2006 Jul-Sep;29(3):238-49
Language
English
Publication Type
Article
Keywords
Advertising as Topic - statistics & numerical data - trends
Bibliometrics
Drug Industry - statistics & numerical data - trends
Drug Prescriptions - statistics & numerical data
Drug Utilization - statistics & numerical data
Humans
Periodicals as Topic
Preventive Medicine - statistics & numerical data
Sweden
Abstract
The objective of this study was to survey how introduction of new drugs and promotional activities influence drug sales in Sweden. All drugs on the Swedish market were categorized as curative, symptom-alleviating, substitutive, or preventive. The number of new drugs introduced, drug sales in volume and value, and the number of drug advertisements appearing in the major Swedish medical journal during 1986-2002 were determined for each of the 4 drug categories. Between 1986 and 1998, the relative shares of the 4 drug categories were relatively constant. From 1998 to 2002, the share of new preventive drugs increased from 24% to 30%, their share of advertisements increased from 20% to 35%, and their sales value increased from 25% to 30%. During the same period, the shares of other drugs decreased correspondingly. Pharmaceutical companies have shifted their attention to the introduction, advertising, and sales of preventive drugs in an attempt to exploit preventive medicine. This might lead to waste of resources when expensive preventive drugs are used by numerous patients over many years, as the benefit of preventive drugs for the individual patient cannot be judged easily.
PubMed ID
16788360 View in PubMed
Less detail

[The new antidepressive agents. Is it rational to prescribe drugs or a "mental brace"?].

https://arctichealth.org/en/permalink/ahliterature210589
Source
Lakartidningen. 1996 Nov 6;93(45):4000-2
Publication Type
Article
Date
Nov-6-1996
Author
J. Håkansson
Author Affiliation
Krokoms hälsocentral.
Source
Lakartidningen. 1996 Nov 6;93(45):4000-2
Date
Nov-6-1996
Language
Swedish
Publication Type
Article
Keywords
Advertising as Topic
Antidepressive Agents, Second-Generation - administration & dosage
Drug Industry - statistics & numerical data - trends
Drug Prescriptions
Drug Utilization - trends
Humans
Physician's Role
Sweden
Notes
Comment In: Lakartidningen. 1996 Dec 4;93(49):45288999235
PubMed ID
8984251 View in PubMed
Less detail